Compare Adaptive Biotechnologies Corp (ADPT) vs Caesars Entertainment Inc (CZR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Caesars Entertainment Inc — how do they compare? Adaptive Biotechnologies Corp trades at $19.86 (market cap $3.33B), while Caesars Entertainment Inc trades at $29.88 (market cap $6.18B). The key difference: Caesars Entertainment Inc is the larger of the two by market cap. Which is the better fit depends on your goals.
| ADPT | CZR | |
|---|---|---|
Market Cap | $3.33B | $6.18B |
Sector | Health | Consumer Cyclical |
52-Week High | $22.37 | $31.51 |
52-Week Low | $10.24 | $18.14 |
Enterprise Value | $3.19B | $30.24B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
CZR trades at $30.35, down 0.13% with a neutral technical stance despite bullish moving averages. The company reported a net loss of $502M in 2025 with negative margins, though revenue grew to $11.49B. Valuation ratios like P/E of 10.42 and P/S of 0.54 appear attractive, but recent earnings misses and a pending acquisition by Fertitta Entertainment at $31.00 per share dominate sentiment. Cash flow trends show improving operational performance with net cash flow narrowing to -$32M in 2025.
The outlook is mixed: the acquisition offers a near-term floor, but operational losses and high debt of $12.03B pose risks. Analysts are cautious with 63.3% hold ratings, citing competitive pressures and integration uncertainties. Investors should weigh the buyout premium against fundamental weaknesses in the leisure sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Caesars Entertainment Inc
Caesars Entertainment includes around 50 domestic gaming properties across Las Vegas (50% of 2021 EBITDAR before corporate and digital expenses) and regional (63%) markets. Additionally, the company hosts managed properties and digital assets, the later of which produced material EBITDA losses in 2021. Caesars' U.S. presence roughly doubled with the 2020 acquisition by Eldorado, which built its first casino in Reno, Nevada, in 1973 and expanded its presence through prior acquisitions to over 20 properties before merging with legacy Caesars. Caesars' brands include Caesars, Harrah's, Tropicana, Bally's, Isle, and Flamingo. Also, the company owns the U.S. portion of William Hill (it plans to sell the international operation in 2022), a digital sports betting platform.
Read more on CZR →
